Clearside Biomedical, Inc. (CLSD)
$
0.8
+0.10 (12.50%)
Key metrics
Financial statements
Free cash flow per share
-4.2822
Market cap
4.2 Million
Price to sales ratio
1.0051
Debt to equity
-0.0109
Current ratio
3.8677
Income quality
0.7840
Average inventory
0
ROE
0.6587
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that aims to transform the delivery of therapies to the back of the eye by utilizing the suprachoroidal space. Among its offerings is XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension designed to treat uveitis macular edema. The company is also advancing the development of CLS-AX, an axitinib injectable suspension currently undergoing Phase 1/2a clinical trials, as well as CLS-301, an integrin inhibitor suspension targeted at treating diabetic macular edema and macular degeneration. The cost of revenue for the company is $149,000.00 showcasing its production and operational expenses. In terms of financial performance, the net income ratio is -20.64 reflecting the company’s profitability margin. The total costs and expenses for the company are $30,546,000.00 indicating its overall spending. Furthermore, the weighted average number of diluted shares outstanding is 4,920,223.00 which reflects potential dilution effects. The company reported an income before tax of -$34,352,000.00 showcasing its pre-tax profitability. Having been incorporated in 2011, Clearside Biomedical is headquartered in Alpharetta, Georgia, and collaborates with notable partners such as Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. In the investment landscape, Clearside Biomedical's stock is affordable at $3.76 making it suitable for budget-conscious investors. The stock has an average trading volume of 234,001.00 indicating moderate liquidity in the market. With a market capitalization of $4,187,215.00 the company is classified as a small-cap player, positioning it as a significant entity in the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within this domain. Additionally, it belongs to the Healthcare sector, which plays a crucial role in advancing medical therapies and technologies that have the potential to improve patient outcomes and quality of life.
What is Clearside Biomedical, Inc. (CLSD)'s stock forecast?
Analysts predict Clearside Biomedical, Inc. stock to fluctuate between $0.37 (low) and $17.10 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Clearside Biomedical, Inc.'s market capitalization?
As of 2025-11-28, Clearside Biomedical, Inc.'s market cap is $4,187,215, based on 5,234,019 outstanding shares.
How does Clearside Biomedical, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Clearside Biomedical, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Clearside Biomedical, Inc. (CLSD) stock?
To buy Clearside Biomedical, Inc. (CLSD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLSD. Place an order (Market, Limit, etc.).
What is the best time to invest in Clearside Biomedical, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Clearside Biomedical, Inc. stock ever split?
Clearside Biomedical, Inc.'s last stock split was 1:15 on 2025-09-15.
How did Clearside Biomedical, Inc. perform in the last earnings report?
Revenue: $1,664,000 | EPS: -$7.05 | Growth: -11.32%.
Where can I find Clearside Biomedical, Inc.'s investor relations reports?
Visit https://www.clearsidebio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Clearside Biomedical, Inc.?
You can explore historical data from here
What is the all-time high and low for Clearside Biomedical, Inc. stock?
All-time high: $7.73 (2021-08-30) | All-time low: $0.29 (2025-07-21).
What are the key trends affecting Clearside Biomedical, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
zacks.com
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $1.5 per share a year ago.
zacks.com
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
globenewswire.com
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME).
zacks.com
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
globenewswire.com
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.
seekingalpha.com
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO Conference Call Participants Jon Wolleben - Citizens Serge Belanger - Needham & Company Debanjana Chatterjee - JonesTrading Yi Chen - H.C. Wainwright Daniil Gataulin - Chardan Operator Greetings, and welcome to the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call.
See all news
